Zydus Lifesciences Dexamethasone Tablets bags USFDA okay
Ahmedabad: Zydus Lifesciences Limited has announced that the Company has received final approval from the United States Food and Drug Administration (USFDA) to market Dexamethasone Tablets USP, 1 mg.
Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer and immune system disorders.
The product will be manufactured at the group’s formulation manufacturing facility at Baddi, Himachal Pradesh.
Dexamethasone Tablets USP, 1 mg had annual sales of USD 1.8 mn in the United States (IQVIA MAT March 24). The group now has 395 approvals and has so far filed over 460* ANDAs since the commencement of the filing process in FY 2003-04.
Furthermore, in the same month, Zydus Lifesciences Limited also received final approval from the USFDA to distribute Dapsone Gel, 7.5% (USRLD: Aczone Gel 7.5%).
Read also: Zydus Lifesciences bags USFDA nod for Dapsone Gel for acne treatment
Headquartered in Ahmedabad, Zydus Lifesciences Limited is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group has a significant presence in cancer-related therapies and offers a wide range of solutions with cytotoxic, supportive & targeted drugs. The group employs over 26,000 people worldwide, including 1,400 scientists engaged in R&D.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.